Floatz logo

Cipralex

Post-Traumatic Stress Disorder

New York State Psychiatric InstitutePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Post-Traumatic Stress Disorder cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB
Duloxetine
Yang I. Pachankis, PhD
Phase 4B

View all 39 →

Same molecule, other indications

Cipralex is also rated in:

Anxiety DisordersDormant
A
Indicative ·
81 / 100
View asset →
bipolar I disorderDormant
BBB
Indicative ·
77 / 100
View asset →
dysthymic disorderDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →